Exelixis reported $1.59B in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 645.73M 28.25M
Acceleron Pharma XLRN:US $ 717.77M 19.84M
Agios Pharmaceuticals AGIO:US $ 1702.56M 652.55M
Akebia Therapeutics AKBA:US $ 331.08M 33.94M
Amgen AMGN:US $ 19099M 2200M
AstraZeneca AZN:LN 27.27B 8.54B
Bayer BAYN:GR 32.45B 3.35B
Biomarin Pharmaceutical BMRN:US $ 2357.84M 69.07M
Bluebird Bio BLUE:US $ 903.53M 194.01M
Bristol Myers Squibb BMY:US $ 29161M 2050M
Cytokinetics CYTK:US $ 364.23M 68.89M
Dicerna Pharmaceuticals DRNA:US $ 616.49M 21.99M
Eisai 4523:JP Y 562507M 44163M
Eli Lilly And LLY:US $ 17295.5M 691M
Esperion Therapeutics ESPR:US $ 275.17M 2.6M
Exelixis EXEL:US $ 1593.25M 158.98M
Genmab GEN:DC 20.3B 367M
Glaxosmithkline GSK:US $ 17566M 958M
Immunogen IMGN:US $ 274.4M 45.18M
Macrogenics MGNX:US $ 367M 7.72M
Mirati Therapeutics MRTX:US $ 1278.09M 25.42M
Moderna Inc MRNA:US 10.97B 734M
Nektar Therapeutics NKTR:US $ 1056.15M 42.9M
Neurocrine Biosciences NBIX:US $ 1110.1M 24.7M
Novartis NOVN:VX 23.81B 1.61B
Puma Biotechnology PBYI:US $ 167.75M 3.99M
Seattle Genetics SGEN:US $ 3098.51M 5.18M
Takeda 4502:JP Y 2476458M 236435M
Ultragenyx Pharmaceutical RARE:US $ 949.49M 121.44M
Xencor XNCR:US $ 480.97M 110.2M
YTE INCY:US $ 2620.06M 170.09M